MA28151A1 - Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations - Google Patents

Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations

Info

Publication number
MA28151A1
MA28151A1 MA29005A MA29005A MA28151A1 MA 28151 A1 MA28151 A1 MA 28151A1 MA 29005 A MA29005 A MA 29005A MA 29005 A MA29005 A MA 29005A MA 28151 A1 MA28151 A1 MA 28151A1
Authority
MA
Morocco
Prior art keywords
imidazolyl derivatives
bicyclic pyrazolyl
pyrazolyl
bicyclic
imidazolyl
Prior art date
Application number
MA29005A
Other languages
English (en)
Inventor
Philip Albert Carpino
Robert Lee Dow
David Andrew Griffith
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28151A1 publication Critical patent/MA28151A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dérivés de pyrazolyle et d¿imidazolyle bicycliques et leurs utilisations Des composés de formule (I) sont décrits dans le présent mémoire. Les composés se sont révélés jouer le rôle de ligands des récepteurs de cannabinoïdes et sont donc utiles dans le traitement de maladies liées à la médiation des récepteurs de cannabinoïdes chez des animaux.
MA29005A 2003-11-07 2006-05-05 Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations MA28151A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51828003P 2003-11-07 2003-11-07

Publications (1)

Publication Number Publication Date
MA28151A1 true MA28151A1 (fr) 2006-09-01

Family

ID=34572986

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29005A MA28151A1 (fr) 2003-11-07 2006-05-05 Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations

Country Status (29)

Country Link
US (2) US7151097B2 (fr)
EP (1) EP1682554A1 (fr)
JP (2) JP4056549B2 (fr)
KR (1) KR20060086396A (fr)
CN (1) CN1886407A (fr)
AP (1) AP2006003601A0 (fr)
AR (1) AR046831A1 (fr)
AU (1) AU2004286909A1 (fr)
BR (1) BRPI0416299A (fr)
CA (1) CA2544752A1 (fr)
CR (1) CR8387A (fr)
DO (1) DOP2004001024A (fr)
EA (1) EA009742B1 (fr)
EC (1) ECSP066549A (fr)
GT (1) GT200400226A (fr)
HR (1) HRP20060166A2 (fr)
IL (1) IL175283A0 (fr)
IS (1) IS8426A (fr)
MA (1) MA28151A1 (fr)
MX (1) MXPA06005023A (fr)
NL (1) NL1027434C2 (fr)
NO (1) NO20062618L (fr)
OA (1) OA13280A (fr)
PA (1) PA8616801A1 (fr)
PE (1) PE20050576A1 (fr)
TN (1) TNSN06129A1 (fr)
TW (2) TW200716135A (fr)
WO (1) WO2005044822A1 (fr)
ZA (1) ZA200603594B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
KR20070051921A (ko) * 2004-09-27 2007-05-18 화이자 프로덕츠 인코포레이티드 이환 피라졸릴 화합물의 제조 방법
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2605479A1 (fr) * 2005-04-20 2006-10-26 Pfizer Products Inc. Composes acylaminobicycliques comportant un heteroatome et leurs utilisations
WO2006129193A2 (fr) * 2005-05-27 2006-12-07 Pfizer Products Inc. Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
EP1951678A1 (fr) * 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Composes pyrazole presentant une activite antagoniste du recepteur cannabinoide (cb1)
WO2007060525A2 (fr) 2005-11-28 2007-05-31 Pfizer Products Inc. Procédé de synthèse de composés bicycliques de type pyrazolyle et imidazolyle
AU2007219236B2 (en) * 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2008048648A2 (fr) * 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Composés modulant cb1 et utilisation de ces derniers
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
US20090062253A1 (en) * 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
JP5530438B2 (ja) * 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
US9549006B2 (en) * 2013-07-31 2017-01-17 Cisco Technology, Inc. Self-adaptive sample period for content sharing in communication sessions
EP3744715A1 (fr) * 2013-11-08 2020-12-02 Incyte Holdings Corporation Procédé pour la synthèse d'un inhibiteur de l'indoléamine 2,3-dioxygénase
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
US11191814B2 (en) 2018-09-04 2021-12-07 Paw Power, Inc. Pet food formulation with cannabinoids
CA3147074A1 (fr) 2019-08-09 2021-02-18 Nihon Nohyaku Co., Ltd. Derive d'oxepinone, insecticide a usage agricole et horticole contenant ledit derive, et son procede d'utilisation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
EP1432708B1 (fr) * 2001-09-24 2005-11-30 Bayer Pharmaceuticals Corporation Preparation et utilisation de derives de la 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine pour le traitement de l'obesite
GB0207249D0 (en) 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7423031B2 (en) 2003-05-01 2008-09-09 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2524397A1 (fr) * 2003-05-07 2004-11-18 Pfizer Products Inc. Ligands de recepteurs cannabinoides et leurs applications
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
KR20070051921A (ko) * 2004-09-27 2007-05-18 화이자 프로덕츠 인코포레이티드 이환 피라졸릴 화합물의 제조 방법

Also Published As

Publication number Publication date
EP1682554A1 (fr) 2006-07-26
TW200716135A (en) 2007-05-01
MXPA06005023A (es) 2006-07-06
AP2006003601A0 (en) 2006-04-30
ECSP066549A (es) 2006-10-17
TWI280245B (en) 2007-05-01
US20070027133A1 (en) 2007-02-01
WO2005044822A1 (fr) 2005-05-19
NL1027434A1 (nl) 2005-05-10
PA8616801A1 (es) 2006-05-16
ZA200603594B (en) 2007-09-26
NO20062618L (no) 2006-08-07
CR8387A (es) 2007-05-30
AU2004286909A1 (en) 2005-05-19
JP2007302685A (ja) 2007-11-22
NL1027434C2 (nl) 2007-11-27
TW200526669A (en) 2005-08-16
IL175283A0 (en) 2006-09-05
PE20050576A1 (es) 2005-09-14
GT200400226A (es) 2005-09-06
JP2007510707A (ja) 2007-04-26
JP4056549B2 (ja) 2008-03-05
EA200600647A1 (ru) 2006-10-27
DOP2004001024A (es) 2005-05-14
HRP20060166A2 (en) 2006-10-31
US20050101592A1 (en) 2005-05-12
CN1886407A (zh) 2006-12-27
OA13280A (en) 2007-01-31
BRPI0416299A (pt) 2007-01-23
IS8426A (is) 2006-04-21
CA2544752A1 (fr) 2005-05-19
KR20060086396A (ko) 2006-07-31
US7151097B2 (en) 2006-12-19
AR046831A1 (es) 2005-12-28
TNSN06129A1 (fr) 2007-11-15
EA009742B1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
TNSN05190A1 (fr) DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES
TNSN05317A1 (fr) Ligands des recepteurs de cannabinoides et leurs utilisations
MXPA05007938A (es) Ligandos de receptores de cannabinoides y usos de los mismos.
MXPA05010164A (es) Ligandos de receptores de canabinoides y sus usos.
MXPA05011362A (es) Ligandos de receptor cannabinoide y usos de los mismos.
TNSN06129A1 (fr) Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
KR102684364B1 (ko) 질환의 치료를 위한 kdm1a 저해제
SG148071A1 (en) Purine compounds and use thereof as cannabinoid receptor ligands
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
PA8601201A1 (es) Ligandos del receptor cannabinoide y usos de los mismos
MXPA05011922A (es) Ligandos del receptor de cannabinoides y sus usos.
MA27766A1 (fr) Ligands de recepteurs de cannabinoides et leurs utilisations
BRPI0411617A (pt) derivados de pirimidina como ligantes de receptores de canabinóides
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
WO2007020502A3 (fr) Ligands des recepteurs de cannabinoide et utilisations de ceux-ci
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
DE60309739D1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
TW200609231A (en) Mglur1 antagonists as therapeutic agents
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
ATE496922T1 (de) Mglur1-antagonisten als therapeutische wirkstoffe
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung